Farmas USA

ADXS

Creo que nadie había colgado esto:

21-3-2016
Data Shows Reduction in Metastatic Disease and Increased Survival in Canine Osteosarcoma Published in Clinical Cancer Research

“We were able to use the Advaxis Lm Technology to induce an antigen-specific T-cell response against HER2/Neu which is expressed in both canine and pediatric osteosarcoma, with only low-grade, transient side-effects."

The median survival time for the ADXS-HER2 treated dogs was 956 days which was significantly longer than the 423 day median survival time of the historical control group (p=0.014, HR 0.33; 95% CI 0.136-0.802).

https://finance.yahoo.com/news/survival-results-advaxis-her2-targeted-110500029.html

AMRN

La FDA no parece que vaya a quedarse muy quieta

"What it does recognize — and what it shows that the FDA is sort of forced to recognize — is that there is a place for truthful, non-misleading information that is off label," Stansel told Business Insider. "It's encouraging in the sense that the FDA has sort of been forced to recognize that there is a place for that kind of a conversation."

https://finance.yahoo.com/news/us-government-just-said-drugmaker-195900964.html

ja,ja puro vicio es lo tuyo!!

Pero esta claro que si se deja meter ... hay que meterla.

Por cierto, en la ultima subida la clavaste al milimetro justo antes de que se girara!!!

TGTX

jiji y fuera en 8,34 gap intradía cerrado y a la espera otra vez :))

Si sube pues nada, si baja pues igual los 7,67-9 son posibles.

TGTX

TIG

Os dejo las últimas noticias de Tigenix, que no las había colgado

18-3-2016

Notice in relation to the convertible bonds due 2018

Conversion Price for the Bonds has been adjusted downwards, following the placement by the Company announced on March 10, 2016 of 25,000,000 new shares at an issue price of € 0.95 per new share, or € 23,750,000 in total, with cancellation of the preferential subscription rights for the existing shareholders of the Company. As a consequence, the Calculation Agent has determined that the Conversion Price is to be adjusted from its previous level of € 0.9414 to the new level of € 0.9263 per TiGenix share (after rounding in accordance with Condition 6.6 of the Terms and Conditions of the Bonds). The Conversion Price adjustment became effective on March 14, 2016.

17-3-2016

TiGenix Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016

a single injection of Cx601 achieved statistically significant superiority vs. placebo in the primary efficacy endpoint of combined remission at week 24 (defined as clinical assessment of closure of all treated external openings draining at baseline, despite gentle finger compression, and absence of collections >2cm confirmed by MRI; p=0.024). This definition of remission is more stringent than those commonly used in clinical trials on perianal fistulizing disease, as it includes both clinical and radiological assessment by MR

https://finance.yahoo.com/news/tigenix-presents-24-week-results-181009458.html#morequotes

10-3-2016

Tigenix raises 23.75 million euros in private placement
25 million shares at an average price of 0.95

7-3-2016
positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients

2-3-2016
submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Cx601 for the treatment of complex perianal fistulas in adult patients with Crohn's diseaseobtained the license for commercial production of Cx601, TiGenix's product for the treatment of complex perianal fistulas in Crohn's disease patients
"This timely and successful achievement fulfils one of the final requirements for our plan to file a Marketing Approval Application for Cx601 at the European Medicines Agency (EMA) in the coming weeks," said Maria Pascual, VP Regulatory Affairs. "In this way our plan remains in line with the expectation to make Cx601 available to European patients in the second half of 2017
https://finance.yahoo.com/news/tigenix-obtains-commercial-production-license-060936709.html

Y, como recordatorio, tiene previsto subir al Nasdaq

bueno, pues gap de apertura cerrado y con ello muchos stocks tambien ,,, veremos ahora que ...

IBB

Hace unos dias me indicastes el subyacente LABU que po cierto tenia un peligro que .... hoy salvo que este mal su cotización la veo + 300% en un solo dia , sabes algo ?

VCEL,quiere romper maximos otra vez.

Esta desde el dia que doblo ha seguido subiendo escalonadamente,,la verdad es que no se lo que puede hacer,yo entre tarde ,a 4 pero voy a esperar aunque no tengo un referente claro de adonde quiere ir..

Y volvi a entrar 4$.